FORX-428
Advanced Solid Tumors (treatment-resistant cancers)
Phase 1Active
Key Facts
Indication
Advanced Solid Tumors (treatment-resistant cancers)
Phase
Phase 1
Status
Active
Company
About FoRx Therapeutics
FoRx Therapeutics is a Swiss clinical-stage biotech focused on a novel oncology approach: targeting DNA Replication Stress. Its lead asset, FORX-428, is a potential best-in-class PARG inhibitor currently in a first-in-human trial, with initial data expected mid-2026. The company is backed by a USD 50M Series A financing round and is led by a team with deep expertise in cancer biology, DNA damage response, and drug development. FoRx aims to address significant unmet need in cancers that develop resistance to current therapies.
View full company profile